«Cancer is like a person's thumbprint; each person's cancer is uniquely theirs,» says Bill Hearl, CEO of Immunomic Therapeutics,
a clinical stage biotechnology company developing a nucleic acid immunotherapy platform with the potential to treat cancer, allergies and animal health issues.
CAMBRIDGE, Mass., April 27, 2017 — Moderna Therapeutics,
a clinical stage biotechnology company that is pioneering messenger RNA (mRNA) Therapeutics ™ to create a new generation of transformative medicines for patients, today announced positive interim data from an ongoing Phase 1 study of mRNA - 1440, an mRNA infectious disease vaccine against avian H10N8 influenza, demonstrating mRNA - 1440 induced high levels of immunogenicity, and was safe and well tolerated.
CAMBRIDGE, Mass., July 13, 2017 — Moderna Therapeutics,
a clinical stage biotechnology company that is pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced new data demonstrating that its Zika mRNA vaccine prevented Zika virus transmission from pregnant mice to their fetuses.
Plc is
a clinical stage biotechnology company, which focuses on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion.